Infection-induced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis: A systematic review

Kakoullis, Loukas; Parperis, Konstantinos; Papachristodoulou, Eleni; Panos, George

doi:10.1016/j.clim.2020.108595

Cited by 25 publications

(24 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many AAV‐associated conditions have been published in case reports, 8 which speculate on possible causes including that any drug could cause vasculitis in persons with a susceptible genotype or that patients could already have been ANCA‐positive, with the culprit medication simply making the disease more pronounced. More commonly, any infection (influenza and other viral, bacterial or fungal infections) can induce ANCA, which may disappear after the infection resolves, and importantly, vasculitis does not necessarily result from positive ANCA 2 . Associations of vasculitis have also been reported for influenza, hepatitis A and B, rubella, smallpox, tetanus, tuberculosis and human papillomavirus vaccines; however, the evidence is from case reports 8 .…”

Section: Discussionmentioning

confidence: 99%

“…Studies have proposed that an inflammatory process, such as an infection or drug reaction, may stimulate ANCA to cause either direct endothelial toxicity or indirectly recruit another autoimmune reaction through a hyperinflammatory state. 2 Although the second mechanism is not well understood, several conditions can lead to a hyperinflammatory state, including predisposing genetics, exposures (silica), drugs (hydralazine, minocycline, propylthiouracil, allopurinol, rifampicin), malignancy and autoimmune conditions. Additionally, viral and bacterial infections and an inflammatory response after a vaccination have also been identified as risk factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of COVID‐19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Felzer

Fogwe

Samrah

et al. 2021

Respirology Case Reports

View full text Add to dashboard Cite

Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)‐associated vasculitis (AAV). Although quite rare, AAV may occur with SARS‐coronavirus disease 2019 (COVID‐19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID‐19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID‐19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of COVID‐19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Felzer

Fogwe

Samrah

et al. 2021

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

“…That is, anti-virus-specific antibodies produced by plasmablasts form immune complexes, leading to activation of complement and release of vasoactive anaphylatoxins [85]. Other than that, the presence of infection-induced anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is reported [86].…”

Section: Vasculopathymentioning

confidence: 99%

“…85 Other than that, the presence of infection-induced anti-MPO antineutrophil cytoplasmic antibody-associated vasculitis is reported. 86 As for the treatment of autoimmune vasculitis in COVID-19, methylprednisolone, cyclophosphamide, and Thrombosis and Haemostasis © 2021. The Author(s).…”

Section: Vasculopathymentioning

confidence: 99%

Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic

2021

View full text Add to dashboard Cite

A number of viral infectious diseases have emerged or reemerged from wildlife vectors that have generated serious threats to global health. Increased international traveling and commerce increase the risk of transmission of viral or other infectious diseases. In addition, recent climate changes accelerate the potential spread of domestic disease. The Coronavirus disease 2019 (COVID-19) pandemic is an important example of the worldwide spread, and the current epidemic will unlikely be the last. Viral hemorrhagic fevers, such as Dengue and Lassa fevers, may also have the potential to spread worldwide with a significant impact on public health with unpredictable timing. Based on the important lessons learned from COVID-19, it would be prudent to prepare for future pandemics of life-threatening viral diseases. Among the various threats, this review focuses on the coagulopathy of acute viral infections since hypercoagulability has been a major challenge in COVID-19, but represents a different presentation compared to viral hemorrhagic fever. However, both thrombosis and hemorrhage are understood as the result of thromboinflammation due to viral infections, and the role of anticoagulation is important to consider.

show abstract

“…Almost 10% have no clinical finding at all, and other auto‐antibodies were found in association in 76%, suggesting a polyclonal response to non‐vasculitis inflammatory triggers 45 . Non‐AAV MPO is more often found in association with other autoimmune conditions than non‐AAV proteinase 3, for which infection is the most common association 47,48 …”

Section: Mpo‐anca and Lung Diseasementioning

confidence: 99%

Myeloperoxidase and associated lung disease: Review of the latest developments

Keat

2021

Int J of Rheum Dis

View full text Add to dashboard Cite

Myeloperoxidase (MPO) anti‐neutrophil cytoplasmic antibodies (ANCA) are often detected in association with a variety of lung pathologies, the most common being interstitial lung disease (ILD). A growing cohort of patients are being diagnosed with MPO‐ANCA in the context of ILD without ANCA‐associated vasculitis. Clinically and radiologically, there is little to differentiate this cohort from MPO‐ANCA‐negative ILD patients; however, the pathophysiology is likely different and different treatments are likely required. We present here a brief summary of the proposed pathophysiology of MPO‐ANCA‐positive ILD, and a more detailed review of the latest evidence on management, including monitoring for development of ANCA‐associated vasculitis, immunosuppression, anti‐fibrotics, and novel agents that have yet to be trialled in human experiments.

show abstract

Infection-induced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis: A systematic review

Cited by 25 publications

References 31 publications

Association of COVID‐19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Association of COVID‐19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis

Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic

Myeloperoxidase and associated lung disease: Review of the latest developments

Contact Info

Product

Resources

About